• Tidak ada hasil yang ditemukan

42Temas Fact Sheet 3Q2017

N/A
N/A
Protected

Academic year: 2018

Membagikan "42Temas Fact Sheet 3Q2017"

Copied!
3
0
0

Teks penuh

(1)

PT PELAYARAN TEMPURAN EMAS, Tbk

FACT SHEETS

For the nine months ended 30 September 2017/2016 (Un-audited)

Income Statements

In Rp Million

Q3-2017

Q3-2016

% Change

Volume (TEUs)

296,180

230,408

28.55

Service Revenue:

Shipping

914,534

859,392

6.42

Stevedoring

498,886

360,640

38.33

Service Revenue

1,413,420

1,220,032

15.85

Gross Profit

200,142

307,523

(34.92)

Income For The Year

(10.624)

155,505

(106.83)

EBITDA

297.327

371,295

(19.92)

Financial Highlights

in %

Q3-2017

Q3-2016

% Change

Gross Profit Margin

14

25

(44)

Net Profit Margin

(0.75)

13

105.77

EBITDA Margin

21

30

(30)

Operating Cash Flow

(in Million

IDR)

(22,556)

443,665

105.08

Financial Ratio

Ratio

Q3-2017

Q3-2016

A/R turnover (days)

39

32

Net Debt to EBITDA

5.60X

2.73X

Interest Bearing Debt to Total Asset

60%

48%

Debt Equity Ratio

193%

132%

Current Ratio

0.59

0.65

Balance Sheets

In Rp Million

Q3-2017

2016

Q3-

In Rp Million

2017

Q3-

2016

Q3-Cash on cash

equivalent

22,666

102,052

Short-term loan

559,045

378,991

Account

Receivables

207,491

147,453

Account

Payables

152,727

101,337

Inventories

91,406

39,752

Taxes Payable

13,993

5,675

Fixed Asset

2,296,3

20

1,735,3

90

Accrued

expenses and

other liabilities

5,927

91,240

Advances

76,847

69,118

Long-term loan

1,106,5

70

634,911

Other Assets

97,335

38,060

Equity

953,803

919,671

Total Assets

2,792,0

2,131,8

Total Liabilities

2,792,0

2,131,8

(2)

PT PELAYARAN TEMPURAN EMAS, Tbk

FACT SHEETS

For the nine months ended 30 September 2017/2016 (Un-audited)

65

25

and Equity

65

25

LIST OF VESSELS

(as September

30, 2017)

SERVICE COVERAGE of 38 PORTS

Please visit our website at

www.temasline.com

for detail of our Financial Report

Disclaimer: This newsletter may contain forward-looking statements that involve risk and uncertainties. Actual future actions may differ materially from those expressed in forward-looking statements as a result of a number of risk, uncertainties and assumptions. You are cautioned not to place undue reliance on those forward-looking statements, which are based on current view of management on future events.

No

17

KM ESTUARI MAS

537

8

TOTAL

25,785

(3)

PT PELAYARAN TEMPURAN EMAS, Tbk

FACT SHEETS

For the nine months ended 30 September 2017/2016 (Un-audited)

For further inquiry, please contact:

Marthalia Vigita -

Corporate Secretary

Email :

[email protected]

Phone: +62 21 4302388 Mobile: +6287788866009

Jl. Yos Sudarso (By Pass) Kav.33 Sunter Jaya

Jakarta 14350, Indonesia

Referensi

Dokumen terkait

Instead, forward-looking statements are based only on current beliefs, assumptions, and expectations of management regarding the Company’s future growth, network roll out and

In addition, the information contained in this presentation contains projections and forward-looking statements that reflect the company's current views with respect to future

Cautionary note on forward-looking statements: This presentation may contain statements regarding the business of PT Industri dan Perdagangan Bintraco Dharma Tbk and its

Certain statements in this release are or may be forward- looking statements. By their nature, forward looking statements involve a number of risks and uncertainties

Certain statements in this release are or may be forward- looking statements. By their nature, forward looking statements involve a number of risks and uncertainties

PT Bumi Resources Tbk is under no duty to update any of the forward-looking statements after this date to conform such statements to actual results or to reflect the occurrence

Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: i the risk that the proposed

Annual Report 2020 for PT Organon Pharma Indonesia, Tbk (formerly PT Merck Sharp Dohme Pharma, Tbk) with a disclaimer regarding forward-looking